Medidata Solutions announced its latest services offering, Medidata Standards AcceleratorTM, which provides end-to-end support for the Clinical Data Interchange Standards Consortium (CDISC) study data tabulation model (SDTM)–the FDA’s recommended format for electronic submission of case report form data. With this offering, Medidata enables sponsors to satisfy FDA submission guidelines in a repeatable fashion, while reducing time and costs.
Medidata’s services team works with sponsors using the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform throughout the study lifecycle to streamline the preparation of SDTM-ready data and the export of SDTM-compliant datasets. In addition to the best practices utilized by Medidata services professionals, Standards Accelerator includes multiple tools aimed at streamlining the preparation of SDTM-compliant data sets:
A longtime CDISC Corporate Sponsor and Registered Solution Provider, Medidata has had a number of its executives formally recognized by CDISC for their individual contributions to standard definitions and ongoing participation in standard groups. Additionally, Rave was the first to be software product certified on all eight Operational Data Model (ODM) use-cases for full interoperability and sharing of clinical data. Rave also was the first EDC solution to provide clinical data acquisition standards harmonization (CDASH) metadata. Medidata Designer®, a study protocol and design solution, has contributed its model to CDISC’s protocol representation model.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.